SCHEMBL4808093

SCHEMBL4808093

COC(=O)C1C[C@@H](C(=O)OC)N(C(=O)OCc2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
FKBP1A P62942 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PREP P48147 2/20 0.46
HTT P42858 2/20 0.46
MITF O75030 1/20 0.46
MAPT P10636 1/20 0.46
HTR2C P28335 1/20 0.45
CPB1 P15086 1/20 0.45
CYP2C19 P33261 3/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7819386 1.00 POLB (0.50) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL8482453 1.00 POLB (0.50) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL8525578 1.00 POLB (0.50) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL8524021 1.00 POLB (0.50) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL4804132 0.94 SMN1; SMN2 (0.51) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL4804141 0.94 SMN1; SMN2 (0.51) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL4804145 0.94 SMN1; SMN2 (0.51) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL7022852 0.89 POLB (0.49) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL7022855 0.89 POLB (0.49) POLBSMN1; SMN2NPC1RAB9AFKBP1A
SCHEMBL1864842 0.88 POLB (0.52) POLBSMN1; SMN2NPC1RAB9AFKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425633-B2 Pyrrolidine compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2008-09-16 US disclosed
US-20070082932-A1 Pyrrolidine compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2007-04-12 US disclosed
US-5942537-A ADMINISTERING A L-TRANS PYRROLIDINE DERIVATIVE TO INHIBIT THE TRANSPORT OF L-GLUTAMATE OR L-ASPARTATE OR AN EXCITATORY AMINO ACID NEUROTRANSMITTER AWAY FROM A SYNAPSE COMPRISING CONTACTING SYNAPSE WITH PYRROLIDINE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-08-24 US disclosed
EP-0497895-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1992-08-12 EP disclosed
WO-1991006536-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082932-A1 Pyrrolidine compounds DPP4, DPP7, DPP9 POLB 1316/4885SMN1; SMN2 4437/4885NPC1 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.